CVS HEALTH CORPORATION (NYSE: CVS) INVESTOR ALERT:

NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP announces that a shareholder has filed a class action lawsuit on behalf of investors (the “Class”) who purchased securities of CVS Health Corporation (“CVS”) (NYSE: CVS) between 3 May 2023 and 30 April 2024inclusive (the “Lesson”).

For more information, submit a form to the CVS Health Corporation Shareholders Class Action Lawsuit, email Investor Relations Manager Peter Allocco at [email protected] or call (212) 951-2030.

According to the lawsuit, CVS made false and misleading statements about the profitability of its health care benefits business.

If you wish to serve as lead plaintiff for the class, you must submit documents by 10 September 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery is not dependent on your serving as lead plaintiff. If you choose not to take action, you may remain an absent class member.

Representation is on a contingency basis. Shareholders pay neither fees nor expenses.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the firm has been retained by some of the nation’s largest public and private pension funds to oversee their assets and litigate on their behalf. Because of its success in litigating hundreds of class action cases, the firm has been named to the National Law Journal’s “Plaintiffs’ Hot List” thirteen times and has been listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertising is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Past results do not guarantee or predict a similar outcome with respect to future matters.

Contact information:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
[email protected]